## IN THE UNITED STATES PATENT AND TRADEMARKS OFFICE

In re Application of: Cagle et al.

Serial No: NYA

(Continuation Serial No. 10/200,868)

Confirmation No: NYA

(Continuation Confirmation No. 5897)

Filed: November 17, 2003

Examiner: NYA

(Continuation Application: Zohreh Fay)

Group Art Unit: NYA

(Continuation Application: 1614)

ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF THE EYE, EAR

AND NOSE

## Alexandria, VA 22313-1450 on this date: Date: November 17, 2003

Deborah Weinschenk

**CERTIFICATE OF MAILING** 

deposited with sufficient postage to the United States Postal Service as Express Mail EV 124 463 558 US,

I hereby certify that this correspondence is being

addressed to: Mail Stop Patent Applications, Commissioner for Patents, P.O. Box 1450,

Signature: War Wunchenk

## <u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. §1.56 AND §1.97(b)(1)</u>

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

For:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56, Applicants direct the attention of the Examiner to the sixty-six (66) references listed on the attached Form PTO-1449 (Sheets 1-6).

Applicants are submitting copies foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Serial No.: NYA

(Continuation Serial No.: 10/200,868)

Filed: November 17, 2003

Page 2

Applicants request that the listed references be considered during prosecution of this application and made of record herein.

Respectfully submitted,

ALCON RESEARCH, LTD.

Date November 17, 2003

Gregg C. Brown

Reg. No. 30,613

Enclosures:

Form PTO-1449 (6 pages)

Foreign Patent Documents & Non-Patent Literature (35 references)

Address for Correspondence: Gregg C. Brown Alcon Laboratories, Inc. 6201 South Freeway, Mail Code Q-148 Fort Worth, TX 76134-2099 Phone: (817) 551-8663 Docket No. 1732 US F2

Total Total		ATTY. DOCKET NO.		SERIAL NO.					
	Patent & Trademark Office		1732 US F2		NYA				
		ITS CITED BY	APPLICANT						
APPLICANT			Ca	gle et al.					
(Use several sheets if necessary)		FILING DAT	E	GROUP					
			No	ovember 17, 2003		NYA			
			U.S. PA	TENT DOCUMENTS		<del></del>		·	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING D APPROP		
/ZF/	AA1	4,474,751	10/02/84	Haslam et al.					
88888	AB1	4,551,456	11/05/85	Katz					
	AC1	4,670,444	06/02/87	Grohe et al.					
00000000	AD1	4,710,495	12/01/87	Bodor					
	AE1	4,730,013	03/08/88	Bondi et al.					
00000000	AF1	4,844,902	07/04/89	Grohe					
00000000	AG1	4,920,120	04/24/90	Domagala et al.					
	AH1	4,980,470	12/25/90	Masuzawa et al.					
***************************************	AI1	4,990,517	02/05/91	Petersen, et al.					
800000	AJ1	4,996,335	02/26/91	Bodor			-		
V	AK1	5,059,597	10/22/91	Petersen et al.					
			FOREIGN	PATENT DOCUMENTS	<del></del>		ı		
	:	DOCUMENT NUMBER	DATE	DATE COUNTRY	CLASS	SUBCLASS	TRANSL	ATION	
							YES	NO	
/ZF/	AL1	CA 2,086,914	07/11/93	Canada			х		
0000	AM1	EP 0 982 031	03/01/00	Europe			х		
	AN1	ES S/N 08320	04/20/93	Spain				X	
	AO1	WO 90/01933	03/08/90	WIPO			X		
V	AP1	WO 96/39146	12/12/96	WIPO		<u></u>	x	<u></u>	
				ling Author, Title, Date, Pe					
/ZF/	AR1	on five new 'respira (1999)	Blondeau, Joseph M., "A review of the comparative in-vitro activities of 12 antimicrobial agents, with focus in five new 'respiratory quinolones', <u>Journal of Antimicrobial Chemotherapy</u> , vol. 43, Suppl. B, pages 1-11 1999)						
/ZF/	AS1	93-97 (1998) (no tr	fluoroquinolones in the treatment of ENT infections", Chemotherapie Journal, 7/3, pages ranslation); XP000892813						
/ZF/	AT1	Ernst et al., "Levof Am. J. Health-Syst	Inst et al., "Levofloxacin and trovafloxacin: The next generation of fluoroquinolones?", Clinical Review, m. J. Health-Syst. Pharm., vol. 54, pages 2569-2584 (114/15/97)						

EXAMINER /Zohreh Fay/ (09/16/2009)

DATE CONSIDERED

FORM PTO-1449		T. OF COMMERCE	ATTY. DOCKET NO.		SERIAL NO.				
	Pate	nt & Trademark Office		1732 US F2	NYA				
		ITS CITED BY	APPLICANT						
	APPLICANT		Cagle et al.						
(Use several sheets if necessary)		FILING DAT	E	GROUP					
			No	ovember 17, 2003		NYA			
			U.S. PA	TENT DOCUMENTS			FILING D	ATEUE	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	APPROP		
/ZF/	AA2	5,149,694	09/22/92	Cagle et al.					
***************************************	AB2	5,164,402	11/17/92	Brighty					
0000000	AC2	5,185,337	02/09/93	Fujii, deceased et al.					
0000000	AD2	5,223,493	06/29/93	Boltralik					
0000000	AE2	5,416,096	05/16/95	Petersen et al.					
	AF2	5,480,879	01/02/96	Petersen et al.					
0000	AG2	5,520,920	05/28/96	Castillo, et al.			-		
000000	AH2	5,540,930	07/30/96	Guy et al.					
	AI2	5,563,138	10/08/96	Ueda et al.			_		
	AJ2	5,597,560	01/28/97	Bergamini et al.				l	
V	AK2	5,607,942	03/04/97	Petersen et al.					
			FOREIGN	PATENT DOCUMENTS		1	<u> </u>	<u></u>	
		DOCUMENT NUMBER	DATE	DATE COUNTRY	CLASS	SUBCLASS	TRANSL	ATION	
		1	i				YES	NO	
/ZF/	AL2	WO 98/06435	02/19/98	WIPO			Х		
0000	AM2	WO 99/15172	04/01/99	WIPO			x		
	AN2	WO 00/18386	04/06/00	WIPO			х		
	AO2	WO 00/18387	04/06/00	WIPO			X		
V	AP2	WO 00/18388	04/06/00	WIPO	1 1 P	T4-)	X		
		OTHER PRIOR	ART (Includ	ling Author, Title, Date, Pe	rtinent Page	recistance and	clinical asr	nects"	
/ZF/	AR2	Medicinal Research	<u>Reviews, vo</u>	ntibacterials: SAR mechanis ol. 16, pages 433-486 (1996)				<del></del>	
/ZF/	AS2	S88 (03/15/1999);	penetration of trovafloxacin into the eye and CSF of rabbits", IOVS, vol. 40, no. 4, page ); XP-000892619						
/ZF/	AT2	Kraseman et al., "E skin structure infec XP000892776	officacy of M tions", <u>Jornal</u>	ficacy of Moxifloxacin against Staphylococcus aureus in respiratory tract and skin and ons", <u>Jornal Of Antimicrobial Chemotherapy</u> , vol. 44, no. Suppl. A, pp 150 (7/99);					

/Zohreh Fay/ (09/16/2009)

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449		T. OF COMMERCE	ATTY. DOCKET NO. SI		SERIAL NO.				
	Pate	ent & Trademark Office		1732 US F2	NYA				
•			1732 0312						
		ITS CITED BY	APPLICANT						
	APPLICA	NT		C2	igle et al.				
(I ice	several sheets i	f necessary)	FILING DAT		GROUP				
(830	Several Silvers	,,				NYA			
				ovember 17, 2003		NIA			
		DOCUMENT.	U.S. PA	TENT DOCUMENTS	T 1	<del></del>	FILING D	ATEIF	
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	APPROP		
/ZF/	AA3	5,631,004	05/20/97	Cagle et al.					
9000	AB3	5,665,373	09/09/97	Robertson et al.		_			
0000000	AC3	5,679,665	10/21/97	Bergamini et al.					
	AD3	5,849,752	12/15/98	Grunenberg et al.					
	AE3	5,854,241	12/29/98	Hallenbach et al.					
000000	AF3	5,912,255	06/15/99	Bussell					
000000000000000000000000000000000000000	AG3	6,093,417	07/25/00	Petrus					
00000000	АН3	6,440,964	08/27/02	Cagle, et al.					
	AI3	6,509,327	01/21/03	Cagle, et al.					
00000000	AJ3								
V	AK3								
			FOREIGN	PATENT DOCUMENTS			T		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
		NOWIBER	DATE				YES	NO	
/ZF/ ·	AL3	WO 00/18404	04/06/00	WIPO	1		Х		
, <u>r.</u> ,	AM3	EP 1 025 846	08/90/00				х		
80000	AN3	WO 01/45679	06/28/01	WIPO				X	
V	AO3	WO 01/89495	11/29/01	WIPO			Х		
	AP3								
		OTHER PRIOR	ART (Includ	ing Author, Title, Date, Pe	rtinent Page	es, Etc.)			
/ZF/	AR3	IOVS vol 40 no 4	nage S689	oical trovafloxacin in a rabbit (03/15/1999) XP-000892625	i				
/ZF/	AS3	NCCLS Document	t M7-A4, "Methods for Dilution Antimicrobial Susceptability Tests for Bacteria That						
	AT3	Grow Aerobically", "New Antimicrobia	l Agents Apr	proved by the U.S. Food and	Drug Admir	istration in 199	7 and New		
/ZF/		Indications for Prev	iously Appro	oved Agents" Antimicrobial	Agents and (	Chemotherapy, v	vol. 42, no.	4, pages	
987-988 (4/1/98); XP000872060									

EXAMINER	/Zohreh Fay/ (09/16/2009)	DATE CONSIDERED
II .	/=====================================	

		ATTY. DOCKET NO.		SERIAL NO.						
	Pate	ent & Trademark Office	1732 US F2			NYA				
LIST OF D	OCÚMEN	NTS CITED BY	APPLICANT							
APPLICANT (Use several sheets if necessary)		Cagle et al.								
		FILING DATE					-			
		Nove	ember 17, 2003		NYA					
			U.S. PATE	NT DOCUMENTS						
EXAMINER		DOCUMENT	NAME OF ACCUMENTS				FILING DATE IF S APPROPRIATE			
INITIAL		NUMBER	DATE	NAME	CLASS	SUBCLASS	ATTROI	KIATE		
	AA4									
	AB4		<u> </u>							
	AC4									
	AD4					· · · · · · · · · · · · · · · · · · ·				
	AE4									
	AF4									
	AG4									
	AH4						<u> </u>	-		
	AI4									
	AJ4									
	AK4				l					
	,		FOREIGN PA	ATENT DOCUMENT	<u> </u>	T	<del> </del>			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
							YES	NO		
	AL4									
	AM4									
	AN4									
	A04									
	AP4					<u> </u>		<u> </u>		
				Author, Title, Date, l				<del></del>		
/ZF/	AR4	NG et al., "Treatm American Journal	NG et al., "Treatment of experimental staphylococcus epidermidis endophthalmitis with oral trovafloxacin" American Journal of Ophthalmology, vol. 216 (2), pages 278-287 (08/1998)							
/ZF/	AS4		of Japan, vol. 1998, no. 10 (08/31/1998), JP 10 130148 05/19/1998 abstract							
/ZF/	AT4	Patent Abstracts of	Japan, vol. 012,	no. 472 (12/09/1988),	JP 63 190826	08/08/1988 abs	tract			

EXAMINER	/Zohreh Fay/ (09/16/2009)	DATE CONSIDERED
1		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SERIAL NO.

Patent & Trademark Office			1732 US F2		NYA					
LIST OF DOCUMENTS CITED BY APPLICANT			APPLICANT							
			Cagle et al.							
(Use	several sheets it	f necessary)	FILING DATE	C	GROUP					
				vember 17, 2003		NYA				
			U.S. PAT	ENT DOCUMENTS		<del></del>	- THE THICK P	ATELE		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE NAME CLASS SUBCLA		SUBCLASS	FILING DATE IF APPROPRIATE				
1	AA5									
	AB5									
	AC5						<del></del>			
	AD5									
	AE5									
	AF5							-		
	AG5									
	AH5									
	AI5									
	AJ5									
	AK5			DAMENIC DOCUMENTS						
<u> </u>	1	DOCUMENT	FOREIGN	PATENT DOCUMENTS	<u> </u>	<u> </u>				
		NUMBER	DATE	COUNTRY	CLASS	CLASS SUBCLASS	TRANSI	LATION		
							YES	NO		
	AL5									
	AM5									
	AN5						<u> </u>			
	AO5							<u> </u>		
	AP5				N di und Pro-	E4a)	<u> </u>			
	T	OTHER PRIOR	ART (Includi	ng Author, Title, Date, F	ertinent Pag	es, Etc.)		neeting of		
/ZF/	AR5	the Society for Ped	Pediatric Research, 104th Annual Meeting of the American Pediatric Society and the 63rd Annual meeting of the Society for Pediatric Research, vol. 35, no. 4, Part 2, page 191A, Seattle, Washington (05/02-05/94)							
/ZF/	AS5			rnal Otitis", Larynyoscope						
/ZF/	AT5	Tillotson, G. S., "C Microbiology, vol.	Quinolones: str 44, pages 320	ructure-activity relationshi -324 (1996)	ips and future	predictions", <u>J.</u>	of Medical	- <del></del>		
EXAMINER /7	ohreh Fav	v/ (09/16/2009)		DATE CONSIDERED						
EVAMPLED: Init	ial if reference	considered whether or no	ot citation is in cor	nformance with MPEP 609; Dra	w line through ci	tation if not in confe	ormance and r	not		

ATTY. DOCKET NO.

U.S. DEPT. OF COMMERCE

FORM PTO-1449

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPT. OF COMMERCE		T. OF COMMERCE	ATTY. DOCKET NO.		SERIAL NO.				
		nt & Trademark Office	1732 US F2		NYA				
		ITS CITED BY	APPLICANT						
	APPLICANT			Са	igle et al.	_			
(Use several sheets if necessary)		FILING DATI	E	GROUP					
			No	vember 17, 2003	NYA				
			U.S. PAT	TENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE NAME CLASS SUBCLA		SUBCLASS	FILING DATE IF APPROPRIATE			
	AA6								
	AB6				<u> </u>				
	AC6				<u> </u>			-	
	AD6								
	AE6								
	AF6			,	<u> </u>				
	AG6								
	AH6			TO CHANNE					
			FOREIGN	PATENT DOCUMENTS	Т —				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI	LATION	
							YES	NO	
	AI6					<u> </u>			
				ng Author, Title, Date, Pe					
	AJ6	administration of si Chemotherapy, vol	ngle intravend 39, Suppl. B,	s and safety of trovafloxacin ous doses of the prodrug, ala pages 75-80 (01/01/1997)	trofloxacin"	, <u>Journal of Ant</u>	imicrobia!		
	AK6	Weiss, Lee R., "Th Managed Care, vol	Lee R., "Therapeutic Pathways for Antimicrobial Use: General Overview", The American Journal Of ged Care, vol. 4, no. 10, Sup., pages S543-S549 (1988)						
	AL6	Quinolones, (Sipor (1990)	, Mark P., "Structure-activity relationships of fluoroquinolones", The New Generation of es, (Siporin, C., Heifetz, C. L. & Domagala, J. M., Eds), pages 1-43, Marcel Dekker, New York						
	AM6	of 11 Other Oral A and Animal Bite W Chemotherapy, Jul	al., "In Vitro Activity of Bay 12-8039, a New 8-Methoxyquinolone, Compared to the Activities Oral Antimicrobial Agents Against 390 Aerobic and Anaerobic Bacteria Isolated from Human Bite Wound Skin and Soft Tissue Infections in Humans", Antimicrobial Agents and py, July 1997, pages 1552-1557						
	AN6	and 11 Other Orga Antimicrobial Age	l Antimicrobia nts and Chemo	n Vitro Activities of Azithro al Agents Against 194 Aerol <u>otherapy,</u> May 1995, pages	oic and Aner 1097-1100	obic Bite Woun	d Isolates"	, 	
	AO6	Rubinstein, "Pharm Meeting date 1999	Pharmacology – Tissue Distribution", <u>International Moxifloxacin Symposium</u> , 1 <sup>st</sup> (2000) 1999, pages 130-133; Editors: Mandell, Lionel						

EXAMINER	DATE CONSIDERED